People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Kura Oncology, Inc. | — | Biotechnology | Series D+ | $241.7M | $1.9B | 2024 |
HELEN COLLINS at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside HELEN COLLINS on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| TROY WILSON | 1 | 7 |
| Faheem Hasnain | 1 | 5 |
| HEIDI HENSON | 1 | 5 |
| YI LIU | 1 | 4 |
| Mary Szela | 1 | 3 |
| PINGDA REN | 1 | 3 |
| ANNETTE NORTH | 1 | 2 |
| ANTONIO GUALBERTO | 1 | 2 |
| Teresa Bair | 1 | 2 |
| DIANE PARKS | 1 | 2 |
| THOMAS MALLEY | 1 | 2 |
| KATHLEEN FORD | 1 | 2 |
| STEPHEN DALE | 1 | 1 |
| BRIAN POWL | 1 | 1 |
| CAROL SCHAFER | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.